181 results about "Brain damage" patented technology

The invention relates to a bionic nano CO generator as well as preparation and application thereof, belongs to the technical field of medicines, and solves the problem that a CO delivery system which can synergistically promote neuroprotection and neurogenesis and has brain targeting and controlled release capabilities is urgently required to be developed at present. According to the technical scheme, the bionic nano CO generator comprises a drug-loaded particle inner core and a covering film, the drug-loaded particle inner core comprises hollow mesoporous CeO2 nano particles and MnCO loaded on the hollow mesoporous CeO2 nano particles, and the covering film is a macrophage membrane and wraps the drug-loaded particle inner core. The compound is used for apoplexy treatment administration by integrating neuroprotection and enhancing innovative dual channels of endogenous nerve growth, and is expected to significantly reduce brain injury after cerebral apoplexy and restore neurological functions so as to relieve the worry about high death rate and long-term disability after cerebral ischemia-reperfusion injury.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention relates to a compound of formula (I) wherein R1 is a hydrogen atom, halogen or -(C1-C2)alkyl, R2 is -halo(C1-C2)alkoxy, and R3 and R4 form together with N to which they are attached an optionally substituted 5-7 membered monocyclic heterocycloalkyl ring or an optionally substituted 8-11 membered bicyclic heterocycloalkyl ring. The present invention also relates to a medicament and a pharmaceutical composition comprising said compound of formula (I), as well as their therapeutic uses, in particular as inhibitor of NOD-like receptor protein 3 inflammasome for preventing and / or treating Parkinson's disease, frontotemporal Dementia, Multiple System Atrophy, Alzheimer's disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis or brain injury.

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.

The application discloses a wearable brain injury local temperature control treatment device and belongs to the technical field of brain injury treatment. The device is provided with a mounting bottom plate, a rotating frame, a waste glue storage box, a moving strip, a glue coating scraper and an adjusting screw sleeve. The connecting top strip is tightly arranged on the top of the adjusting screw sleeve. The minimum distance between the glue coating scraper and the mounting bottom plate is limited. An appropriate amount of gel is applied on the edge of the temperature control sheet. The moving strip is pushed to drive the glue coating scraper to move on the top of the mounting bottom plate. The glue coating scraper pushes the gel to be applied on the top of the temperature control sheet. The gel can be uniformly applied on the surface of the temperature control sheet. The gel on the surface of the temperature control sheet is not uniformly applied. The contact between the temperature control sheet and the skin is not uniform. The heat transfer and distribution are affected. When the glue coating scraper passes through the temperature control sheet, the excess gel is pushed to flow from the top of the trapezoidal inclined block to the waste glue storage box. The excess gel is prevented from being left on the mounting bottom plate, so that the surface of the mounting bottom plate is not sticky.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention discloses a novel neurophotoelectrode, comprising: a chip for vertically emitting modulated laser light to an electrode structure; and an electrode structure with its tip positioned away from the chip, capable of simultaneously transmitting optical and electrical signals. Both the chip and the electrode structure utilize a flexible silicon substrate, are coupled together, and encapsulated within a flexible material. This novel neurophotoelectrode is a new brain electrode structure combining a silicon photonic waveguide (PIC) with a flexible Utah electrode. Besides transmitting and receiving neuronal electrical signals, it can achieve deeper stimulation via laser light. Furthermore, utilizing the PIC chip's MZ modulation technology, it can achieve targeted and quantitative optical signal stimulation based on feedback signals. Its flexibility reduces brain damage, while simultaneously achieving photoelectric stimulation, increasing stimulation depth, and expanding its application scope, demonstrating broad application prospects.

The invention discloses an application of abscisic acid in preparation of a medicine for improving secondary brain injury after cerebral hemorrhage, the abscisic acid can relieve neuroinflammation and improve neurological function recovery by repairing microglial cell lysosome functions, enhancing phagocytic ability and promoting hematoma removal, and a new medicine strategy is provided for cerebral hemorrhage treatment.

The application discloses a nano guanido drug system and a preparation method and application thereof, and relates to the technical field of medicine, in particular to a GCOF DHM @CAQK platform, can efficiently deliver drugs to a TBI injury site, can accumulate in a TBI brain injury area, can inhibit neuroinflammation, oxidative stress and protect neuron cells after TBI, can precisely intervene in secondary injury of TBI, and provides a new strategy for improving the prognosis of patients.

The present disclosure relates to a compound of formula (I) which is in crystalline Form 1, characterized by having a powder X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 3.3, 10.0, 20.1, 21.7, and 25.0. The present disclosure also relates to processes for its preparation, as well as a medicament and a pharmaceutical composition comprising it. The present disclosure further concerns the crystalline Form 1 of compound of formula (I) for use as a medicine and more particularly in the prevention and / or in the treatment of Parkinson's disease, frontotemporal dementia, multiple system atrophy, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, or brain injury.

Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.

The application discloses a brain injury identification method and an identification system. The identification system identifies the injury of a patient according to the identification method. The identification method comprises the following steps: firstly, the electrical impedance tomography (EIT) of the brain of the patient is performed to obtain the EIT image of the brain of the patient; then, the region with abnormal resistivity distribution in the EIT image of the brain is taken as a reference for scanning of a near-infrared spectrometer, and a scanning path of the near-infrared spectrometer is planned; finally, the near-infrared spectrometer is scanned along the scanning path, and the lesion range and the lesion type are determined according to the obtained near-infrared spectral data. The electrodes need not be arranged on the whole head of the patient, and the automatic and rapid identification of the lesion range and the nature of the brain injury is realized.

This invention relates to the field of chemiluminescence detection technology for in vitro diagnostic reagents, specifically to an S100-β chemiluminescence detection kit and its preparation method. It provides a chemiluminescence detection kit for central nervous system-specific proteins using magnetic microparticles. The kit comprises: S100-β calibrator, S100-β monoclonal antibody conjugated with carboxyl magnetic beads, S100-β monoclonal antibody labeled with alkaline phosphatase, AMPPD chemiluminescence substrate solution acted upon by alkaline phosphatase, and concentrated washing buffer. This kit achieves the following: no sample pretreatment required, easy operation, high automation, high sensitivity, automatic result output in 16 minutes, good stability of calibrator and enzyme label, and low cost. It can meet the clinical needs for auxiliary diagnosis and treatment of acute ischemic brain injury.

This invention relates to the use of 5α-androsta-3β,5,6β-triol and its derivatives in the prevention or treatment of radiation-induced brain injury, and to methods for preventing or treating radiation-induced brain injury with 5α-androsta-3β,5,6β-triol and its derivatives.

The application discloses a nasopharyngeal carcinoma radioactive brain damage image auxiliary judgment method, equipment and medium, the method is: collecting MRI image and preprocessing, segmenting the temporal lobe region, using the temporal lobe region and corresponding lesion annotation training level prediction model of MRI image, the probability that a single temporal lobe image region exists radioactive brain damage lesion is predicted;With the probability that each subject all layers contain lesions output by the level prediction model as input, whether the subject exists radioactive brain damage as output, training patient level prediction model;Finally, the trained level prediction model and patient level prediction model are used to obtain the incidence probability of radioactive brain damage of a single nasopharyngeal carcinoma subject, when multiple modes coexist, the average of multiple mode prediction result outputs is taken as the final prediction result. The application can judge whether the corresponding nasopharyngeal carcinoma brain MRI image exists radioactive brain damage according to the input, provide reference for clinical doctors to diagnose, and reduce the missed diagnosis of nasopharyngeal carcinoma radioactive brain damage.

Techniques for detecting embolic information for a patient. The techniques may include obtaining data identifying an ultrasound signal associated with the patient, identifying a set of candidate embolic regions in the data, identifying a set of embolic regions from among the set of candidate embolic regions, and outputting embolic information corresponding to the set of embolic regions.

Disclosed are compounds, compositions, and methods for inhibiting tyrosine-mediated DNA repair in a neuroprotective manner and / or activating transcription and / or protein synthesis. Compositions include a resveratrol, such as cis-resveratrol, or a compound of Formula I or Formula II. Compounds of Formula I and Formula II have the following structureswhere the variables, e.g., Y1, Y2, Y3, R1, R2, R3 the A-ring, and W are defined herein. Said compound and compositions may be utilized in treating aging and age-associated neurocognitive and metabolic disorders including various types of cancer. In particular, compositions disclosed herein are neuroprotective against tyrosine / phenylalanine or their metabolites-mediated neurodegeneration and neurocognitive disorders. The disclosure also includes combination pharmaceutical compositions and methods of treatment in which cis-resveratrol, a compound of Formula I, a compound of Formula II, or a pharmaceutically acceptable salt thereof is used in combination with a GLP-1 receptor agonist for treating a traumatic brain injury or a neurodegenerative disorder.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The application discloses a kind of bioengineered apoptotic bodies based on apoptotic body membrane protein and liposome and preparation method and application thereof.The bioengineered apoptotic bodies are formed by the chimerization of apoptotic body membrane protein and liposome loaded with gastrodin and Cy5.The bioengineered apoptotic bodies simulating the natural apoptosis process of mesenchymal stem cells can promote the polarization of microglial cells to M2 type, release anti-inflammatory factors and neurotrophic factors, promote the proliferation of neurons, improve the antioxidant capacity of cells, improve the nervous motor function, relieve brain edema, and thus effectively treat traumatic brain injury.

To provide a material for treating encephalopathy, a method for treating encephalopathy, a material for regenerating brain neuron, and a method for regenerating brain neuron.MEANS: The present invention provides a material for treating encephalopathy or the like, containing a support fixed or coated with at least one selected from the group consisting of N-cadherin, a fusion protein containing the whole or some parts of N-cadherin, and a fusion protein containing the whole or some parts of a protein having homology with N-cadherin.SELECTED DRAWING: Figure 4

The present invention relates to a sulfonylurea derivative and medical uses thereof, specifically relating to the sulfonylurea derivative shown in general formula (I), a preparation method thereof, a pharmaceutical composition containing same, and a use of same for treating diseases and disorders affected by neuronal damage, for example: cerebral stroke, brain damage, neuropathic pain, migraines, inflammatory pain, chronic pain, or depression. The definition of each group in the general formula (I) is the same as that in the description.

The invention discloses application of bitter gourd exosomes in regulating intestinal flora. The method comprises the following steps: establishing an Alzheimer's disease mouse model, injecting the extracted balsam pear exosome into the mouse body in a gavage manner to serve as an experimental group drug, taking normal saline as a model negative control group, detecting the change of the intestinal flora of the AD mouse by applying a 16S amplicon sequencing principle, and detecting the change of the intestinal flora metabolite of the AD mouse by applying an LS-MS technology. An open field experiment, a nesting experiment and a water maze experiment are adopted to verify the treatment effect of the balsam pear exosome on AD mouse intestinal flora and metabolic level changes thereof. Results prove that the bitter gourd exosome extracted by the invention can effectively improve the intestinal flora micro-ecology of AD mice; the compound can be used for preparing a microecological preparation for regulating intestinal flora of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, different types of spinal cerebellar ataxia and the like and diseases such as cerebral apoplexy, cerebral injury, epilepsy, tumor and the like.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The application discloses application of YL-0919 in treatment of epilepsy or brain injury caused by epilepsy. The application proves through animal experiments that YL-0919 has a good effect of treating epilepsy or brain injury caused by epilepsy. The research result of the application provides a new method and thought for clinical treatment.

The invention discloses application of a gene editing virus interfering expression and secretion of enzyme prototype cathepsin D in brain trauma, belongs to the field of gene functions and application, and finds that brain injury is aggravated and nerve dysfunction is aggravated due to the fact that the level of the enzyme prototype cathepsin D in plasma is increased due to the brain trauma through detection. The mechanism is as follows: the enzyme prototype cathepsin D enhances the transendocytosis effect of cerebral vascular endothelial cells after brain trauma, so that plasma inflammatory factors are gathered in damaged brain tissues; meanwhile, the expression of cerebrovascular endothelial cells VCAM-1 is also up-regulated, and neutrophil infiltration in an injured brain region after brain trauma is intensified. Research finds that down-regulation of plasma enzyme prototype cathepsin D can alleviate inflammatory factor concentration and neutrophil density in a brain injury area after trauma, and alleviate neurological function impairment of mice. Aiming at the functions of the plasma prototype cathepsin D, a strategy for reducing the plasma level of the plasma prototype cathepsin D by a gene editing technology for interfering the prototype cathepsin D is provided for treating the cerebral trauma.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

3H-pyrazolo[4,3-f]quinoline compounds that inhibit interferon gene-stimulating factor (STING); compositions comprising the same compounds; and their use for the treatment of STING-related diseases, such as STING-related inflammatory diseases, autoimmune diseases, diabetes, cancer, traumatic brain injury, and fibrosis.

The invention relates to mammalian mesenchymal stem cells (MSCs) for use in a method of treatment of a hypoxic-ischemic brain injury (HIBI) event in a human neonate. Particular routes of administration are disclosed. The invention also encompasses the MSCs for use in a method of prevention of the consequences and / or treatment of a neurodevelopmental disability in a neonate which has suffered or is suspected of suffering a HIBI event. A ready to use device for the administering of MSCs to human neonates is also disclosed.